|
|
|
 |
 |
|
       |
|
|
|
News | June 10, 2002  Protein Sciences announces licensing of patented swine influenza vaccine Meriden, CT, June 10, 2002 - Protein Sciences Corporation (PSC) announced today that it has entered into a research and license agreement for its patented swine influenza vaccine with a leading international developer, producer and distributor of biological products for animal diseases. The agreement provides for an up-front payment, milestones based on successful completion of various development stages and royalties on product sales. Manon Cox, PSC's Vice President, Corporate and Process Development, commented, "Our patented recombinant hemagglutinin influenza vaccine has shown safety and efficacy in veterinary use and in preliminary tests in swine. We look forward to working with an industry leader and are confident that by combining our resources with those of our licensee we can quickly bring this product to market. She added, "Licenses for other veterinary applications are available." Ms. Cox also stated, "We are in active discussions with several companies regarding licensing of human uses of our patented influenza vaccines, recombinant hemagglutinin and recombinant neuraminidase, that have shown safety and efficacy in extensive Phase I and II clinical trials." She added, "We expect to conduct clinical studies of a trivalent recombinant hemagglutinin vaccine with the National Institutes of Health before year end and move into Phase III clinical trials soon thereafter." Founded in 1983, Protein Sciences Corporation (www.proteinsciences.com) is the world leader in developing genes coding for proteins into commercial human and veterinary vaccines, therapeutics and diagnostics using its proprietary baculovirus expression vector system (BEVS) technology that includes its patented expresSF+® serum free, high yielding, scalable insect cell line. Customers access PSC's proprietary BEVS technology through its GeneXpress® program. This allows them to obtain cGMP human and animal clinical materials more reliably, rapidly and less expensively than through alternative protein expression systems. |
|
|
|
||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
